Novartis CD20 Antibody Treatment Multiple Sclerosis Phase 3 Results Positive

MS is a chronic disease of the central nervous system (CNS), which disrupts the normal function of the brain, optic nerve and spinal cord through inflammation and tissue damageProgress of MS leads to an increase in loss of physical function (e.gwalking) and cognitive function (e.gmemory)There are three main types of MS: recurrent remission MS (RRMS), secondary progressive MS (SPMS) and primary progressive MS (PPMS)RMS is characterized by a well-defined relapse and remission process, i.erelapse, seizure, or deterioration, followed by a partial or full recovery periodGlobally, about 2.3 million people with MS, about 85 percent of MS patients are initially diagnosed with RMSOfatumab is a completely human-derived CD20 antibodyBy binding to CD20 on the surface of B lymphocytes, it is able to remove B cells from the blood, which play an important role in stimulating autoimmune responses in MS patientsThe treatment allows patients to be given a monthly, subcutaneous injection at homeNot only for the control of the disease provides convenience, but also can better target the B cells in the lymphatic rhythm, reducing the damage to B cells in the spleenPreviously, ofumumab had been approved by the FDA as a leukemia treatmentA total of 1,882 MS patients in theparticipated in the 30-month ASCLEPIOS trialThe trial consisted of two double-blind, randomized trials, which were a head-to-head comparison trial, comparing the safety and efficacy of the treatment of MS adult patients with teriflunomideThe results showed that the main clinical endpoint struck at reducing the annual recurrence rate (ARR) of MS compared with the active control groupIts critical secondary endpoints for delaying the progression of the disease have also been metOfatumab also demonstrates good safety and continuous efficacy" It is clear that early intervention albeit can improve long-term outcomes in patients with MSAt the moment, MS is still one of the highly unmet medical needs, and we expect strong and convenient therapies to emerge," said Professor Stephen LHauser, director of the UCSF Weill Institute for Neuroscience"
References:s1, Novartis of-atumab Arsussus Aubagio® in two head-to-head Phase III multiple from the multiple sclerosis, Retrieved August 30, 2019, https://